Cargando…
Programmable multistage drug delivery to lymph nodes
Therapeutic delivery selectively to lymph nodes has the potential to address a variety of unmet clinical needs. However, owing to the unique structure of the lymphatics and the size-restrictive nature of the lymph node reticular network, delivering cargo to specific cells in the lymph node cortex an...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305972/ https://www.ncbi.nlm.nih.gov/pubmed/32523099 http://dx.doi.org/10.1038/s41565-020-0679-4 |
_version_ | 1783548571763605504 |
---|---|
author | Schudel, Alex Chapman, Asheley Poole Yau, Mei-Kwan Higginson, Cody James Francis, David Mark Manspeaker, Margaret Patricia Avecilla, Alexa Regina Chu Rohner, Nathan Andrew Finn, M.G. Thomas, Susan Napier |
author_facet | Schudel, Alex Chapman, Asheley Poole Yau, Mei-Kwan Higginson, Cody James Francis, David Mark Manspeaker, Margaret Patricia Avecilla, Alexa Regina Chu Rohner, Nathan Andrew Finn, M.G. Thomas, Susan Napier |
author_sort | Schudel, Alex |
collection | PubMed |
description | Therapeutic delivery selectively to lymph nodes has the potential to address a variety of unmet clinical needs. However, owing to the unique structure of the lymphatics and the size-restrictive nature of the lymph node reticular network, delivering cargo to specific cells in the lymph node cortex and paracortex is difficult. Here, we describe a delivery system to overcome lymphatic and intra-lymph node transport barriers by combining nanoparticles that are rapidly conveyed to draining lymph nodes after administration in peripheral tissues with programmable degradable linkers. This platform enables the controlled release of intra-lymph-mobile small molecular cargo, which can reach vastly more immune cells throughout the lymph node than either the particles or free compounds alone. The release rate can be programmed, allowing access to different lymph node structures and thus, specific lymphocyte subpopulations. We are thereby able to alter the subtypes of drugged lymph node cells to improve immunotherapeutic effects. |
format | Online Article Text |
id | pubmed-7305972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
record_format | MEDLINE/PubMed |
spelling | pubmed-73059722020-12-10 Programmable multistage drug delivery to lymph nodes Schudel, Alex Chapman, Asheley Poole Yau, Mei-Kwan Higginson, Cody James Francis, David Mark Manspeaker, Margaret Patricia Avecilla, Alexa Regina Chu Rohner, Nathan Andrew Finn, M.G. Thomas, Susan Napier Nat Nanotechnol Article Therapeutic delivery selectively to lymph nodes has the potential to address a variety of unmet clinical needs. However, owing to the unique structure of the lymphatics and the size-restrictive nature of the lymph node reticular network, delivering cargo to specific cells in the lymph node cortex and paracortex is difficult. Here, we describe a delivery system to overcome lymphatic and intra-lymph node transport barriers by combining nanoparticles that are rapidly conveyed to draining lymph nodes after administration in peripheral tissues with programmable degradable linkers. This platform enables the controlled release of intra-lymph-mobile small molecular cargo, which can reach vastly more immune cells throughout the lymph node than either the particles or free compounds alone. The release rate can be programmed, allowing access to different lymph node structures and thus, specific lymphocyte subpopulations. We are thereby able to alter the subtypes of drugged lymph node cells to improve immunotherapeutic effects. 2020-06-10 2020-06 /pmc/articles/PMC7305972/ /pubmed/32523099 http://dx.doi.org/10.1038/s41565-020-0679-4 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Schudel, Alex Chapman, Asheley Poole Yau, Mei-Kwan Higginson, Cody James Francis, David Mark Manspeaker, Margaret Patricia Avecilla, Alexa Regina Chu Rohner, Nathan Andrew Finn, M.G. Thomas, Susan Napier Programmable multistage drug delivery to lymph nodes |
title | Programmable multistage drug delivery to lymph nodes |
title_full | Programmable multistage drug delivery to lymph nodes |
title_fullStr | Programmable multistage drug delivery to lymph nodes |
title_full_unstemmed | Programmable multistage drug delivery to lymph nodes |
title_short | Programmable multistage drug delivery to lymph nodes |
title_sort | programmable multistage drug delivery to lymph nodes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305972/ https://www.ncbi.nlm.nih.gov/pubmed/32523099 http://dx.doi.org/10.1038/s41565-020-0679-4 |
work_keys_str_mv | AT schudelalex programmablemultistagedrugdeliverytolymphnodes AT chapmanasheleypoole programmablemultistagedrugdeliverytolymphnodes AT yaumeikwan programmablemultistagedrugdeliverytolymphnodes AT higginsoncodyjames programmablemultistagedrugdeliverytolymphnodes AT francisdavidmark programmablemultistagedrugdeliverytolymphnodes AT manspeakermargaretpatricia programmablemultistagedrugdeliverytolymphnodes AT avecillaalexareginachu programmablemultistagedrugdeliverytolymphnodes AT rohnernathanandrew programmablemultistagedrugdeliverytolymphnodes AT finnmg programmablemultistagedrugdeliverytolymphnodes AT thomassusannapier programmablemultistagedrugdeliverytolymphnodes |